sperimentazione

PTC518 is a small molecule capable of reducing the protein that causes Huntington's disease.

Pivot-HD: new hope for the treatment of Huntington Disease

PTC518 is a small molecule capable of reducing the protein that causes Huntington's disease (HD).

Finally Good news for the Huntington's community!

We received yesterday the official communication from uniQure, announcing that the enrollment of the first patient cohort in the study of ATM-130 for the treatment of Huntington's disease has concluded, ahead of schedule.

But the good news don't end here: a new clinical trial with AMT-130 will be initiated in Europe by the end of the year.